Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice
Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice
复制标题
DOI：
10.1016/j.clim.2006.12.002
复制
发表时间：
2007-04-01
影响因子：
8.6
通讯作者：
Vandenbark, Arthur A.
中科院分区：
文献类型：
--
作者：
Link, Jason M.;Rich, Cathleen M.;Vandenbark, Arthur A.
人类自身免疫性疾病如多发性硬化症（MS）的治疗可能需要能够预防或逆转导致临床复发和疾病进展的炎症过程的药物。我们评估了新设计的单体重组TCR配体（RTL 342 M）的能力，该配体含有与MOG-35-55肽共价连接的HLA-DR 2肽结合结构域，以预防和治疗HLA-DR 2转基因小鼠实验性自身免疫性脑脊髓炎（EAE）的初始发作和随后复发。i.v.或s.c.对HLA-DR 2小鼠产生了麻痹性EAE临床体征的快速（24小时内）和剂量依赖性逆转，甚至单剂量
Treatment of human autoimmune diseases such as multiple sclerosis (MS) will likely require agents that can prevent or reverse the inflammatory process that results in clinical relapses and disease progression. We evaluated the ability of a newly designed monomeric recombinant TCR ligand (RTL342M) containing HLA-DR2 peptide-binding domains covalently linked to MOG-35-55 peptide to prevent and treat both the initial episode and subsequent relapses of experimental autoimmune encephalomyelitis (EAE) in HLA-DR2 transgenic mice. Single doses of RTL342M given either i.v. or s.c. to HLA-DR2 mice produced a rapid (within 24 h) and dose-dependent reversal of clinical signs of paralytic EAE, and even a single dose